Literature DB >> 11516972

PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease.

K Wada, A Nakajima, R S Blumberg.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a nuclear receptor that is known to play a central role in adipocyte differentiation and insulin sensitivity. Through work in several animal models of intestinal inflammation, it is now recognized that PPARgamma also inhibits tissue injury associated with immune activation. These studies point to PPARgamma as a novel anti-inflammatory mediator with broad therapeutic potential.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11516972     DOI： 10.1016/s1471-4914(01)02076-7

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN： 1471-4914            Impact factor:   11.951


  17 in total

1.  Leptin in intestinal inflammation: good and bad gut feelings.

Authors:  G Matarese; R I Lechler
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

2.  Creeping fat in Crohn's disease: travelling in a creeper lane of research?

Authors:  A Schäffler; H Herfarth
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

3.  Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer.

Authors:  George Theodoropoulos; Ioannis Papaconstantinou; Evangelos Felekouras; Nikolaos Nikiteas; Petros Karakitsos; Dimitris Panoussopoulos; Andreas Ch Lazaris; Efstratios Patsouris; John Bramis; Maria Gazouli
Journal:  World J Gastroenterol       Date:  2006-08-21       Impact factor: 5.742

4.  Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.

Authors:  Salvatore Cuzzocrea; Barbara Pisano; Laura Dugo; Angela Ianaro; Nimesh S A Patel; Rosanna Di Paola; Tiziana Genovese; Prabal K Chatterjee; Massimo Di Rosa; Achille P Caputi; Christoph Thiemermann
Journal:  Br J Pharmacol       Date:  2003-08-11       Impact factor: 8.739

5.  Leptin receptor expression on T lymphocytes modulates chronic intestinal inflammation in mice.

Authors:  B Siegmund; J A Sennello; J Jones-Carson; F Gamboni-Robertson; H A Lehr; A Batra; I Fedke; M Zeitz; G Fantuzzi
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

6.  PPARγ ligand attenuates portal inflammation in the MRL-lpr mouse: a new strategy to restrain cholangiopathy in primary biliary cirrhosis.

Authors:  Yusuke Nozaki; Kenichi Harada; Takahiro Sanzen; Yasuni Nakanuma
Journal:  Med Mol Morphol       Date:  2013-02-09       Impact factor: 2.309

7.  Metabolic cross-talk between skeletal muscle and adipose tissue in high-intensity interval training vs. moderate-intensity continuous training by regulation of PGC-1α.

Authors:  Hossein Shirvani; Ehsan Arabzadeh
Journal:  Eat Weight Disord       Date:  2018-02-26       Impact factor: 4.652

8.  Role of PPARs in Trypanosoma cruzi Infection: Implications for Chagas Disease Therapy.

Authors:  Eugenia Hovsepian; Federico Penas; Gerardo A Mirkin; Nora B Goren
Journal:  PPAR Res       Date:  2012-02-09       Impact factor: 4.964

9.  Infection of specific strains of Streptococcus mutans, oral bacteria, confers a risk of ulcerative colitis.

Authors:  Ayuchi Kojima; Kazuhiko Nakano; Koichiro Wada; Hirokazu Takahashi; Kazufumi Katayama; Masato Yoneda; Takuma Higurashi; Ryota Nomura; Kazuya Hokamura; Yoshinori Muranaka; Nobuyuki Matsuhashi; Kazuo Umemura; Yoshinori Kamisaki; Atsushi Nakajima; Takashi Ooshima
Journal:  Sci Rep       Date:  2012-03-26       Impact factor: 4.379

10.  Effect of pioglitazone treatment on behavioral symptoms in autistic children.

Authors:  Marvin Boris; Claudia C Kaiser; Allan Goldblatt; Michael W Elice; Stephen M Edelson; James B Adams; Douglas L Feinstein
Journal:  J Neuroinflammation       Date:  2007-01-05       Impact factor: 8.322
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.